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Studies on CFTR protein expression and localization in native tissues or in primary cultures of human epithelial cells are scarce due to the
intrinsic instability of this protein, its low expression in most tissues and also to technical difficulties.
However, such data are of the highest importance to understand the pathophysiology of CF. The purpose of this article is to outline several
assays for the characterization of primary epithelial cultures and to review different CFTR immunostaining protocols.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Anti-CFTR antibodies; Immunohistochemistry1. Introduction
CFTR protein is expressed predominately in epithelia
(for a review, see Ref. [1]). The original description of the
CFTR gene was accompanied by analysis of the CFTR
transcript by Northern blotting. Such results evidenced
CFTR expression in the pancreas, sweat glands, intestine,
lung, nasal polyps, and liver [2].
Most of the data on CFTR expression and function,
however, result from studies performed on heterologous
overexpressing cellular models or on immortalized cells1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.008
Abbreviations: Ab, antibody; BSA, bovine serum albumin; IHC,
immunohistochemistry; PFA, paraformaldehyde; PBS, phosphate-buffered
saline; RT, room temperature; TJ, tight junctions; TER, transepithelial
resistance.
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E-mail address: filipa.mendes@insa.min-saude.pt (F. Mendes).endogenously expressing this protein [3]. Although polar-
ized epithelial cell models are the best models to study
expression and interactions of CFTR, they still exhibit
deviations from native tissues brought about by the trans-
formation process.
Very few groups have addressed the issue of CFTR
protein expression in native human tissues or in primary
cultures of human epithelial cells. Thus, the intracellular and
histological distribution of CFTR in healthy controls and in
patients is still poorly documented and data are often
contradictory [4–10].
Direct studies of CFTR localization on human tissue are
hampered by several difficulties, namely: (a) low abundance
of CFTR protein in most tissues where it is endogenously
expressed [11,12]; (b) lack of sensitivity of anti-CFTR
antibodies (Abs) to detect this protein in native tissues
(for a review on anti-CFTR Abs, see Ref. [13]); additionally,
(c) epitopes recognized by some of these Abs frequently
become inaccessible after routine tissue preservationed by Elsevier B.V. All rights reserved.
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challenges to be solved. An additional reason for the
difficulty of these studies in native tissues from patients is
that organs affected by CF such as the airways, pancreas,
and intestine are massively destroyed by inflammation and
remodeling processes.
Clearly, more studies on native tissues are mandatory as
the knowledge obtained is critical to assess the impact of
CFTR mutations on the cellular and subcellular localization
of the protein.
For this purpose, a sensitive and efficient method of
choice is often indirect immunostaining. However, the
quality of the data largely depends on the specificity and
sensitivity of the Abs and on the protocols applied, starting
with the collection of patient cells/tissues and ending in the
observation of the specimens at the microscope. It is thus
crucial for CFTR research in general, and for studies of
CFTR localization in native tissues, particularly the ex-
change of information among researchers on antibodies,
tissue samples, and protocols [15].
The scope of the present article is to review methods for
the localization of CFTR in native tissues and in primary
cultures of epithelial cells. The isolation and primary
culture of human airway epithelial cells are described
elsewhere in this supplement [16–19] and in the literature
[20]. Here, we provide an outline of the assays and tests
necessary to confirm the differentiation and polarization
status of these types of cultures. We also review the impact
of the anti-CFTR immunostaining protocol used in terms
of both preservation of tissue morphology and CFTR
signal detected. The details of the protocols are given
elsewhere [15].1 Claudins and occludins, present in TJs, associate with intracellular
peripheral membrane proteins called ZO proteins (a tight junction is also
known as a zonula occludens) which anchor the strands to the actin
cytoskeleton (see Fig. 1).2. Junctional and polarity markers in primary cultures
of human epithelial cells
At cellular level, the degree of epithelial cell differenti-
ation is of major importance.
In well-differentiated and polarized epithelial cell
cultures, CFTR expression is comparable to that of
freshly isolated cells [20]. When growing primary cul-
tures of epithelial cells, optimal culture conditions have
to be used, so that the cell culture preserves the
ultrastructure, the ion transport properties, and the syn-
thesis and secretion of molecules characteristic of the
tissue from which the cells were originally derived. Thus,
markers of polarity and differentiation should be analysed
to confirm the differentiation status of cells, so that these
are appropriate for CFTR localization and functional
studies.
The plasma membrane of polarized epithelial cells is
divided into two biochemically and functionally distinct
domains, the apical and basolateral plasma membrane.
This distinction generates polarity. Junctional protein
complexes such as tight junctions (TJ), adhering junc-tions, and desmosomes, while playing a fundamental role
in maintaining the polarized phenotype (TJs separate the
apical and basolateral domains), also provide the tight-
ness that is a characteristic of epithelia. Indeed, TJs
selectively regulate the passage of molecules across the
paracellular pathway (gate function) of epithelia and
passively separate molecules into the apical and baso-
lateral plasma domains (fence function). Epithelial cells
thus asymmetrically distribute receptors, transporters, ion
channels, and lipids between the apical and basolateral
membranes to establish and maintain polarity and func-
tion (Fig. 1).
Thus, functional TJs are crucial to maintain the polarized
phenotype of epithelial cells. Several tests can be used to
monitor the existence of functional TJ. The experimental
details and protocols for these tests are described elsewhere
[15].
2.1. To control the presence of tight junctions
In epithelial cell monolayers grown on collagen-coated
filters, two types of methods can be used to visualize the
presence of TJs: transmission electron microscopy and
immunolocalization of TJ proteins such as occludin (rat
monoclonal Ab from Zymed Laboratories, San Francisco,
CA, USA) and ZO-1 protein,1 (mouse monoclonal Ab from
Chemicon International, Temecula, CA, USA).
2.2. To monitor the gate function of TJ
Two assays can be utilized, namely: (1) transepithelial
resistance (TER) measurements with the Ca2 + switch assay
and (2) the lanthanum nitrate permeability test.
The measurement of TER allows the evaluation of the
degree of tightness of the epithelial cells grown on collagen-
coated filters. Commonly used for MDCK cells, the Ca2 +-
switch assay monitors the formation of functional TJ. The
protocol is described in detail elsewhere [15]. Briefly, cells
incubated in Ca2 +-free medium are transferred to medium
containing normal Ca2 + levels, which increases cell-to-cell
contact and initiates assembly of junctional complexes. At
selected times, the presence of TJ proteins is monitored by
measuring the TER.
The lanthanum nitrate permeability test also allows the
verification of the existence of functional TJ. When these
are present, the lanthanum nitrate does not penetrate through
the epithelial intercellular junctions and remains excluded at
the surface of the epithelium. In contrast, if the TJs are
disrupted or improperly formed, the lanthanum nitrate
diffuses through the intercellular spaces and penetrates
through the epithelial barrier.
Fig. 1. Schematic representation of polarized epithelial cells. The junctional complexes and the apical or basolateral distribution of several polarity markers are
shown (adapted from Ref. [15]).
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The characteristic distribution of certain proteins to the
apical or basolateral domains of normal polarized epithelial
tissues makes them useful as polarity markers. Their immu-
nolocalization allows the analysis of the presence and
functionality of TJ. As markers of the apical domain
EBP50 (mouse monoclonal Ab from BD Transduction,
San Diego, CA, USA), ezrin (goat polyclonal Ab from
Santa Cruz Biotechnology, Santa Cruz, CA, USA) or
CD59 (mouse monoclonal Ab from BD Pharmingen, San
Diego, CA, USA) can be used. For the basolateral domain,
two typical proteins are studied: h1 integrin (mouse mono-
clonal Ab from Beckman Coulter, Fullerton, CA, USA) and
Na+–K+ ATPase.3. Immunohistochemistry of CFTR
3.1. Optimization of the immunostaining protocol towards
a good balance between tissue preservation and CFTR
signal
A large part of the observed variability in CFTR immu-
nostaining can be generally due to the protocol used. In fact,
the differences in published results relative to CFTR local-
ization may be explained, to a certain extent, by the lack of
sensitivity of Abs and/or variability of protocols used
among different laboratories.
A protocol of immunohistochemistry (IHC) of CFTR
should result in a good compromise between morphology
preservation (achieved through adequate fixation) and
avoidance of epitope destruction (achieved only if mild
fixation conditions are used). Before testing the specificityand sensitivity of the different anti-CFTR Abs (see Ref.
[13]), optimization of critical steps (fixation, protease inhi-
bition, dilution, and incubation time of primary Ab) should
be performed.
Several studies have compared different fixation proto-
cols and antibodies [7,10,21] using as starting point previ-
ously described IHC protocols for CFTR [12,4 –
6,22,23,8,9].
3.2. Collection of patient cells/tissues
Fresh specimens of human tissues (nasal polyps are
obtained immediately after polypectomy or rectal/colon
biopsies taken during colonoscopy) are immediately im-
mersed in DMEM/F12 medium supplemented with 250 UI/
ml of penicillin, 125 Ag/ml of streptomycin, and 2.5 Ag/ml
amphotericin B and then rinsed with phosphate-buffered
saline (PBS), coated with OCT compound (Tissue Tek,
Miles, IN, USA), and the specimens quickly frozen in liquid
nitrogen and stored at  80 jC until use.
For colon tissue specimens, morphology is much better
preserved, if samples are obtained by cutting off small
pieces of tissue, rather than by a biopsy procedure [10].
This suggests that the additional cell and tissue disruption
observed in intestinal samples when compared with airway
tissue [9] may be associated with the biopsy (forceps)
procedure.
Cryosections (6–8 Am thick) are obtained from frozen
tissues in a cryomicrotome (Reichert-Jung, Bensheim, Ger-
many) at  20 jC, placed onto gelatin or silane-coated glass
slides (Menzel-Glazer, Braunschweig, Germany), air-dried,
and used immediately or stored at  80 jC until use. IHC
studies can be carried out either on fresh or thawed cryo-
sections after air-drying and rehydration for 5 min in PBS.
Fig. 2. Immunodetection of CFTR in human nasal epithelium. Cryofixed
section from nasal polyp showing apical CFTR immunolabeling with
MATG 1061 (Transge`ne, Strasbourg, France).
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The fixation step is very critical because while preserving
the tissue from autolysis, if too drastic, it may also cause a
decreased signal due to concealment/disappearance of the
antigenic motif (epitope).
The most common fixing agents used for CFTR IHC are
methanol, acetone, or paraformaldehyde (PFA) solutions.
It was previously described that PFA-fixing solutions like
the Zamboni’s solution (composed of 85% of solution 1–
2% v/v PFA/0.1 M Sorensen phosphate buffer and 15% of
51.5 mM picric acid [24]) are not suitable for IHC detection
of CFTR [7,10]. Indeed, in Zamboni-fixed sections probed
with anti-CFTR Ab, a CFTR-specific signal was described
to be almost completely absent in intestinal samples and
highly decreased in nasal samples [10]. Indeed, such drastic
fixing conditions must render CFTR epitopes unavailable
for detection.
Generally, methanol and acetone give better results on
cryosections (as described above), while PFA works better
for paraffin-embedded samples.
Without any fixation, labeling of intestinal tissue with
anti-CFTR Abs is still evident but tissue morphology is not
preserved, whereas in unfixed nasal samples, loss of mor-
phology is not observed [10]. This also confirms that CFTR-
IHC is considerably more difficult to perform in human
intestinal tissue than in the airways.
Overall, methanol fixation is chosen for the general
CFTR immunostaining protocol as the best compromise
between CFTR signal and tissue morphology for both
intestinal and nasal tissues.
3.4. Antibodies
For CFTR immunostaining, several Abs have been
evaluated for their sensitivity and specificity towards CFTR.
The results are described elsewhere in this supplement [13].
Anti-cytokeratins 18/19 Abs (mouse monoclonal Ab
AE1–AE3 from Dako, Glostrup, Denmark), staining cyto-
skeletal elements of differentiated epithelial cells, besides
confirming epithelial nature of cells observed in sections,
can be used to assess the preservation of tissue morphology.
Specificity of immunoreactive signals can be confirmed
by the generally accepted negative controls: omission of
CFTR (primary) antibody and/or its replacement by the pre-
immune serum (or isotype control) or by peptide competi-
tion. Furthermore, tissues from CF patients carrying two
nonsense mutations, e.g., R553X, G542X, and W1282X,
can represent the golden-standard negative control, as no
full-length CFTR protein is produced in these cells. How-
ever, these samples are not easy to obtain.
3.5. Optimized protocols
As mentioned above, several studies were performed to
optimize the immunodetection protocol concerning the
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inhibitors, and the use of different incubation times of the
primary Ab [2 h at room temperature (RT) versus overnight
at 4 jC], both on preservation of tissue morphology and on
the CFTR signal detected. These protocols are described in
detail at the European Working Group on CFTR Expression
Web site [15].
Overnight incubation of the primary Ab at 4 jC leads to
a significant loss of tissue morphology compared to 2 h
incubation at RT without significant gain in CFTR labeling
[10]. Therefore, the shorter incubation time with primary Ab
should be used because sample tissue morphology is better
preserved without diminishing the signal.
Proteolytic activity, particularly intense in intestinal tis-
sue samples due to the presence of pancreatic and intestinal
proteases and bacteria [25], may also cause loss of tissue
integrity. Adding a protease inhibitor cocktail (mg/ml):
leupeptin 1; aprotinin 2; benzamidine 121; pefabloc 50;
and E64 3.5, during primary Ab incubation does not
significantly improve the preservation of colon tissue mor-
phology [9].
Briefly, the general protocol consists of fixing the fresh
or thawed cryosections (see above) in methanol for 10 min
at  20 jC or acetone at 4 jC. Alternatively, fixation in 4%
(w/v) PFA for 16 h is used prior to paraffin embedding.
Nonspecific binding sites are blocked with 1–3% (w/v)
BSA solution in PBS (optional) before labeling with anti-
CFTR Ab. Incubation time with primary Abs is usually 1–2
h at RT in a humid chamber. Similar incubation with
secondary Abs lasts for 45 min. Sections are washed three
times for 5 min in PBS between each step and finally
mounted in Vectashield antifading medium (Vector Labs,
Burlingame, CA, USA) containing DAPI (Sigma, St Louis,
MO, USA) for nuclei labeling. Samples can be counter-
stained with Harris’ hematoxylin (Sigma).
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rescence microscope (e.g., Axioskop, Carl Zeiss Optische
Systeme, Go¨ttingen, Germany). Specific staining and neg-
ative controls should always be photographed under iden-
tical conditions (filters, microscope magnification, and
fluorescence exposure time). Fig. 2 provides typical results
obtained with this protocol.Acknowledgements
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